Myopic Macular Degeneration Market Size (7MM) is going to be ~USD 737 million in 2025, and expected to grow with a CAGR of 1.3% by 2034, estimates DelveInsight

DelveInsight's "Myopic Macular Degeneration Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Myopic Macular Degeneration Market by downloading the comprehensive report from DelveInsight @ Myopic Macular Degeneration Therapeutics Market- https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Myopic Macular Degeneration Market Report
• As per DelveInsight's estimations, the total diagnosed prevalent cases of Myopic Macular Degeneration in the 7MM were approximately 4.1 million in 2022 and are projected to increase during the forecast period.
• The overall count of individuals diagnosed with Myopic Macular Degeneration in the United States was approximately 1.1 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, Japan accounted for the highest number of Myopic Macular Degeneration diagnosed cases of around 2 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
• Among EU4 and the UK, France had the highest diagnosed prevalent population of Myopic Macular Degeneration, with about 0.27 million cases, followed by Germany and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In 2022, DelveInsight's analysis of gender-specific diagnosed prevalent Myopic Macular Degeneration cases within the 7MM indicated an approximate distribution of 39% in males and 61% in females.
• The leading Myopic Macular Degeneration Companies such as Roche, Bayer, Regeneron Pharmaceuticals, and others.
• Promising Myopic Macular Degeneration Therapies such as Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and others.

Gain a competitive edge in the Myopic Macular Degeneration Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Myopic Macular Degeneration Treatment Drugs- https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myopic Macular Degeneration Epidemiology Segmentation in the 7MM
• Total Myopic Macular Degeneration Diagnosed Prevalent Cases
• Myopic Macular Degeneration Gender-specific Diagnosed Prevalent Cases
• Total Myopic Macular Degeneration Diagnosed Prevalent cases

Download the report to understand which factors are driving Myopic Macular Degeneration Epidemiology Trends @ Myopic Macular Degeneration Prevalence- https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Myopic Macular Degeneration Drugs
• EYLEA (aflibercept): Bayer/Regeneron Pharmaceuticals
EYLEA is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. EYLEA helps prevent VEGF-A and PLGF from interacting with their natural VEGF receptors in previous clinical trials. While ensuring a commendable safety profile, EYLEA's impact on the market and its cost-effectiveness compared to other treatments are essential considerations. EYLEA, the sole approved mCNV treatment in Japan and Europe with an active patent, dominates the Myopic Macular Degeneration treatment landscape, immune to biosimilar competition.

Emerging Myopic Macular Degeneration Drugs
• VABYSMO (faricimab): Roche
VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and VEGF-A. Faricimab is not present in the pipeline of Roche for the treatment of mCNV, but the trial is registered on CT, which is in Phase III "not yet recruiting" stage.

Discover key developments and opportunities in the Myopic Macular Degeneration Market. Click here to learn more from DelveInsight's latest report @ Myopic Macular Degeneration Market Size- https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myopic Macular Degeneration Companies
Roche, Bayer, Regeneron Pharmaceuticals, and others.

Myopic Macular Degeneration Market Outlook
Myopic maculopathy (Myopic Macular Degeneration), also named Myopic Macular Degeneration and myopic retinopathy, encompassing macular atrophy, lacquer cracks, and choroidal neovascularization (mCNV), is influenced by age and axial length. Strategies like low concentration atropine and optical interventions aim to curb myopic progression. Currently, no available treatment has been found for myopic maculopathy except for mCNV, creating a pressing need for more treatment options. Present treatments for Myopic Macular Degeneration align with wet AMD approaches, utilizing anti-VEGF medications such as LUCENTIS (with an expired patent) and EYLEA.

Download DelveInsight's Myopic Macular Degeneration Market report today and stay ahead in this rapidly evolving field. @ Myopic Macular Degeneration Clinical Trials- https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myopic Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Myopic Macular Degeneration Companies- Roche, Bayer, Regeneron Pharmaceuticals, and others.
• Myopic Macular Degeneration Pipeline Therapies- Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and others.
• Myopic Macular Degeneration Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Myopic Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Myopic Macular Degeneration Market Access and Reimbursement

Table of Contents
1. Key Insights
2. Myopic Macular Degeneration Market Report Introduction
3. Country-wise Myopic Macular Degeneration Market Overview at a Glance
4. Myopic Macular Degeneration Market Overview by Therapeutic Class
5. Methodology of Myopic Macular Degeneration Epidemiology and Market
6. Myopic Macular Degeneration Executive Summary
7. Key Events
8. Myopic Macular Degeneration Disease Background and Overview
9. Myopic Macular Degeneration Epidemiology and Patient Population
10. Myopic Macular Degeneration Patient Journey
11. Myopic Macular Degeneration Marketed Drugs
12. Myopic Macular Degeneration Emerging Drugs
13. Myopic Macular Degeneration: Market Analysis
14. Key Opinion Leaders' Views
15. Myopic Macular Degeneration SWOT Analysis
16. Myopic Macular Degeneration Unmet needs
17. Myopic Macular Degeneration Market Access and Reimbursement
18. Appendix
19. Myopic Macular Degeneration Report Methodology
20. DelveInsight Capabilities
21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.